Methods for treating eye disorders

Details for Australian Patent Application No. 2009308380 (hide)

Owner Quark Pharmaceuticals, Inc.

Inventors Feinstein, Elena; Alpert, Evgenia; Mett, Igor; Bar-Ilan, Amir; Spivak, Igor; Kalinski, Hagar; Slager, Netanja

Agent Cullens

Pub. Number AU-A-2009308380

PCT Pub. Number WO2010/048352

Priority PCT/ IL2009/000179 15.02.09 IL; 61/198,931 11.11.08 US; 61/196,995 22.10.08 US

Filing date 22 October 2009

Wipo publication date 29 April 2010

International Classifications

A61K 31/711 (2006.01) - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

17 March 2011 PCT application entered the National Phase

  PCT publication WO2010/048352 Priority application(s): WO2010/048352

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009308383-Process for enhanced total organic carbon removal while maintaining optimum membrane filter performance

2009308375-Methods and compositions for diagnosis and prognosis of renal injury and renal failure